Exploring Pathophysiological Processes Shared Between Type 2 Diabetes Mellitus and Osteoarthritis
- 1Institute of Anatomy and Cell Biology, Paracelsus Medical Private University Nuremberg and Salzburg, 90419 Nuremberg, Germany
Abstract
Type 2 diabetes mellitus (T2DM) and osteoarthritis (OA) are highly prevalent chronic disorders with increasing global burdens that frequently coexist and share common risk factors, including obesity, aging and chronic low-grade inflammation. This narrative review aims to summarize current evidence regarding the epidemiological, clinical and molecular links between T2DM and OA and to highlight potential therapeutic implications. Growing evidence suggests that T2DM contributes to OA development and progression through multiple interconnected mechanisms. These include advanced glycation end-product (AGE) accumulation, oxidative stress, chronic inflammation, extracellular matrix degradation, impaired autophagy, ferroptosis, mesenchymal stem cell dysfunction and microvascular impairment within joint tissues. In addition, shared genetic and molecular pathways, including AGE–RAGE, IL-17, PI3K/Akt/mTOR and LGR6/Wnt/β-catenin/NRF2 signaling, further support a biological connection between the two diseases. Clinically, T2DM is associated with increased OA severity, enhanced pain sensitization, accelerated disease progression and higher rates of joint arthroplasty. Emerging evidence also suggests that antidiabetic agents, particularly metformin and glucagon-like peptide 1 receptor agonists, may exert disease-modifying effects through anti-inflammatory, metabolic and chondroprotective mechanisms. Overall, T2DM and OA should be regarded as interconnected metabolic-inflammatory disorders. Improved understanding of their shared mechanisms may facilitate earlier intervention, therapeutic repurposing and integrated multidisciplinary management strategies to reduce disease burden and improve patient outcomes.
Related
- Exploring LEPR Gene rs1137100 and rs1137101 Polymorphisms in Gestational Diabetes Mellitus: A Pilot Study From Bangladesh
- Exploring the Role of Umbilical Cord Blood Leptin and Visfatin in Fetal Growth: Associations with Gestational Diabetes Mellitus and Neonatal Anthropometric Measurements
- Exploring the Therapeutic Potential of Metformin and Vitamin D₃ Combination in the Management of Diabetes Mellitus.
- The Ghrelin-LEAP2 System in Obesity and Diabetes: Pathophysiological Roles and Therapeutic Potential
- From Genes to Diets: A Critical Review of Genetic, Nutrigenomic and Epigenetic Mechanisms in Type 2 Diabetes Mellitus
BibTeX
@article{majeed2026exploring,
title = {{Exploring Pathophysiological Processes Shared Between Type 2 Diabetes Mellitus and Osteoarthritis}},
author = {Yasir Majeed and Gundula Gesine Schulze-Tanzil and Maria Kokozidou},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = oct,
doi = {10.3390/ijms27209168},
url = {https://www.mdpi.com/1422-0067/27/20/9168},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Exploring Pathophysiological Processes Shared Between Type 2 Diabetes Mellitus and Osteoarthritis
AU - Yasir Majeed
AU - Gundula Gesine Schulze-Tanzil
AU - Maria Kokozidou
PY - 2026
DA - 2026/10/16
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27209168
UR - https://www.mdpi.com/1422-0067/27/20/9168
AB - Type 2 diabetes mellitus (T2DM) and osteoarthritis (OA) are highly prevalent chronic disorders with increasing global burdens that frequently coexist and share common risk factors, including obesity, aging and chronic low-grade inflammation. This narrative review aims to summarize current evidence regarding the epidemiological, clinical and molecular links between T2DM and OA and to highlight potential therapeutic implications. Growing evidence suggests that T2DM contributes to OA development and progression through multiple interconnected mechanisms. These include advanced glycation end-product (AGE) accumulation, oxidative stress, chronic inflammation, extracellular matrix degradation, impaired autophagy, ferroptosis, mesenchymal stem cell dysfunction and microvascular impairment within joint tissues. In addition, shared genetic and molecular pathways, including AGE–RAGE, IL-17, PI3K/Akt/mTOR and LGR6/Wnt/β-catenin/NRF2 signaling, further support a biological connection between the two diseases. Clinically, T2DM is associated with increased OA severity, enhanced pain sensitization, accelerated disease progression and higher rates of joint arthroplasty. Emerging evidence also suggests that antidiabetic agents, particularly metformin and glucagon-like peptide 1 receptor agonists, may exert disease-modifying effects through anti-inflammatory, metabolic and chondroprotective mechanisms. Overall, T2DM and OA should be regarded as interconnected metabolic-inflammatory disorders. Improved understanding of their shared mechanisms may facilitate earlier intervention, therapeutic repurposing and integrated multidisciplinary management strategies to reduce disease burden and improve patient outcomes.
SN - 1422-0067
ER -